Results 11 to 20 of about 67 (63)

Trastorno bipolar asociado a cabergolina en una paciente joven: caso clínico en un Hospital Nacional en Perú

Psicosomática y Psiquiatría
RESUMEN  La cabergolina, un agonista dopaminérgico utilizado para el tratamiento de la hiperprolactinemia, se ha asociado con la aparición de síntomas psicóticos y alteración en el control de los impulsos, entre otros síntomas psiquiátricos ...
Asiri C. Niño-Puentes, Roger Abanto-Marin, Shirley Quispe-Sigueñas, Gabriela Aspilcuea-Montoya   +3 more
doaj   +1 more source

Impulse control and related disorders in Parkinson’s disease

Arquivos de Neuro-Psiquiatria
Neuropsychiatric disorders are common among patients with Parkinson’s disease and may appear in any stage of the disease. However, these disorders often go undiagnosed and receive insufficient treatment.
Antonio Pedro Vargas, Francisco Eduardo Costa Cardoso   +1 more
doaj   +1 more source

Tratamiento del síndrome neuroléptico maligno

Salud Uninorte, 2011
El síndrome neuroléptico maligno es una complicación grave del tratamiento con psicofármacos. La principal característica es la hipertermia, acompañada de hipertonía muscular, alteración del nivel de conciencia e inestabilidad autonómica.
Franklin Escobar Córdoba, Irina Goretty Polanía-Dussán, Sandra Milena Toro-Herrera   +2 more
doaj  

Efecto de agonistas y antagonistas de la dopamina en ambientes de reforzamiento variables

, 2008
The anhedonia hypothesis maintains that pleasure for food-reward is determined by dopamine activity in the brain. The cumulative body of empirical evidence shows that dopamine agonists and antagonists (e.g., Methylphenidate and Haloperidol, respectively) decrease operant behavior maintained by positive reinforcement.
Jorge Arturo Balderrama-Trápaga, Carlos Fernando Aparicio-Naranjo   +1 more
openaire   +2 more sources

Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert. [PDF]

Rev Neurol, 2022
Kulisevsky J.
europepmc   +1 more source

[Apomorphine and frontal dysfunction in Parkinson's disease]. [PDF]

Rev Neurol, 2022
Fernández-Pajarín G, Martín-Jiménez I, Ares-Pensado B, Sesar-Ignacio A.   +3 more
europepmc   +1 more source

Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit. [PDF]

Rev Neurol, 2023
Morales-Casado MI, García-Meléndez DD, Diezma-Martín A, López-Ariztegui N.   +3 more
europepmc   +1 more source

Time until modification of antiparkinsonian therapy in a group of patients from Colombia. [PDF]

Rev Neurol, 2023
Valencia-Vásquez A, Gaviria-Mendoza A, Ayala-Torres JD, Calvo-Torres F, Machado-Alba JE.   +4 more
europepmc   +1 more source

[Palliative care for people with advanced Parkinson's disease. A systematic review]. [PDF]

Rev Neurol, 2023
Sánchez-Cárdenas MA, Sánchez-Rua M, Sequea-Torregrosa L, Ramírez-Zapata D, Martínez-Martínez MJ, Nitola-Mendoza LM, Noreña-Peña A.   +6 more
europepmc   +1 more source

Medical cannabis: Critical points for clinical application [PDF]

Biomedica, 2022
Gómez-García DM, García-Perdomo HA.
europepmc   +1 more source